secretoglobin family 1D member 2Genealiases: LIPB · LPHB · LPNB
Q-omics provides the consensus-scored SCGB1D2 profile across patient tissues and cancer cell-line models. SCGB1D2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SCGB1D2 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, SCGB1D2 protein abundance shows 15,887 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight UCEC, COAD, and GBM as cancer lineages where SCGB1D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SCGB1D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SCGB1D2 survival associations across molecular data types. SCGB1D2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SCGB1D2 RNA expression–survival associations across cancer types. High SCGB1D2 expression shows unfavorable associations in BLCA, LUAD, THCA and LIHC, but favorable associations in UCEC and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for SCGB1D2 RNA expression.
This table summarizes SCGB1D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for SCGB1D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SCGB1D2 shows lower tumor expression in COAD, THCA, KICH, KIRC, HNSC and BRCA. The COAD box plot shows higher SCGB1D2 RNA expression in normal versus tumor tissue (log2 FC = −0.310, t-test p < 0.001).
This table shows molecular features associated with SCGB1D2 in patient tissues and cancer cell lines. In patient samples, SCGB1D2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SCGB1D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BREAST.
